Paul Weiss Adds Robert F. Masella As M&A Partner In New York

Paul, Weiss, Rifkind, Wharton & Garrison has added Robert F. Masella as a partner in the firm’s M&A Group within its Corporate Department in New York.

Masella is an experienced mergers and acquisitions lawyer and former Bank of America Merrill Lynch managing director who has advised public and private companies, corporate boards, private equity firms and financial institutions on complex domestic and cross-border transactions.

His practice spans public and private M&A, dual-track M&A and IPO processes, joint ventures, option agreements, licensing and collaboration agreements, and spin-offs.

Masella has worked across a wide range of industries, with a particular emphasis on life sciences. He will continue focusing on that sector at Paul, Weiss.

His practice also includes advising boards of directors on corporate governance, shareholder activism, fiduciary duties and conflict-of-interest matters.

Recent transactions include advising SpringWorks Therapeutics in its acquisition by Merck KGaA, Versanis Bio in its acquisition by Eli Lilly, Color Wow in its acquisition by L’Oréal, Proteologix in its acquisition by Johnson & Johnson and Ironshore Therapeutics in its acquisition by Collegium Pharmaceutical.

Masella has also advised Teleflex in its acquisition of Biotronik’s Vascular Intervention business, Ally Bridge Group on multiple investments, Thomson Reuters on multiple acquisitions and major financial institutions on a range of transactions.

Before returning to private legal practice, Masella served as a managing director at Bank of America Merrill Lynch, giving him experience on both the legal and financial sides of complex corporate transactions.

He earned a B.A., magna cum laude, from the College of William & Mary and the London School of Economics, along with a combined J.D./M.B.A., magna cum laude, from the University of Pennsylvania Law School and The Wharton School.

Masella has also served on multiple professional and nonprofit boards and committees, including TheChurch, Law360’s Life Sciences Editorial Advisory Board, the New York Bar Association’s Committee on Mergers & Acquisitions and Corporate Control Contests, and its Corporation Law Committee.

Paul, Weiss’ M&A practice advises private equity firms, public and private companies, financial institutions and investors across strategic acquisitions, divestitures and other complex transactions.

KEY QUOTES

“I have worked closely with Rob over many years. He is a spectacular M&A lawyer and advisor, and I couldn’t be happier that he is joining Paul, Weiss.”

Scott Barshay, Chairman Of Paul, Weiss

“Rob is one of the very best M&A lawyers and a market leader in life sciences. He is an exceptional addition to our team and will create great value for our clients.”

Krishna Veeraraghavan, Global Co-Head Of M&A At Paul, Weiss

“Paul, Weiss’ robust platform and deep life sciences experience make it the ideal home for my practice. I am excited to join such a talented and exceptional team.”

Robert F. Masella, Partner At Paul, Weiss